Tarsus PharmaceuticalsTARS +1.42%48 Quick Ratio is 3.71 as of Mar. 2026, which is 73% below its 10-year median of 13.75. GuruFocus rates TARS with a GF Score™ of 48/100 and a GF Value™ of $201.69 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,417 Biotechnology companies, Tarsus Pharmaceuticals ranks better than 50.95% on this metric.
Tarsus Pharmaceuticals has a quick ratio of 3.71. It generally indicates good short-term financial strength.
The historical rank and industry rank for Tarsus Pharmaceuticals's Quick Ratio or its related term are showing as below:
TARS'
s Quick Ratio Range Over the Past 10 Years
Min: 3.71 Med: 13.75 Max: 70.85
Current: 3.71
During the past 8 years, Tarsus Pharmaceuticals's highest Quick Ratio was 70.85. The lowest was 3.71. And the median was 13.75.
TARS's Quick Ratio is ranked better than 50.95% of 1417
companies
in the Biotechnology industry
Industry Median: 3.6
vs TARS: 3.71
Tarsus Pharmaceuticals (NAS:TARS) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Tarsus Pharmaceuticals Quick Ratio Related Terms
Tarsus Pharmaceuticals Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Tarsus Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tarsus Pharmaceuticals Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tarsus Pharmaceuticals's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Tarsus Pharmaceuticals's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Tarsus Pharmaceuticals's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tarsus Pharmaceuticals (TARS) has a Quick Ratio of 3.71 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Tarsus Pharmaceuticals and its competitors. This is 73% below median its historical median of 13.75. Over the past decade, Tarsus Pharmaceuticals' Quick Ratio has ranged from 3.71 to 70.85. According to the industry distribution chart, Tarsus Pharmaceuticals ranks #695 out of 1417 companies in the Biotechnology industry, placing it in the top 49%.
Is Tarsus Pharmaceuticals' Quick Ratio too high?
Tarsus Pharmaceuticals' current Quick Ratio of 3.71 is 73% below median its 10-year median of 13.75. Over the past 10 years, this metric has ranged from a low of 3.71 to a high of 70.85. The Biotechnology industry median Quick Ratio is 3.60. Tarsus Pharmaceuticals' value of 3.71 is 3.1% above this industry median. Based on the distribution chart, Tarsus Pharmaceuticals ranks #695 out of 1417 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Tarsus Pharmaceuticals has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tarsus Pharmaceuticals' Quick Ratio compare to VERA and IDYA?
According to the Biotechnology industry distribution chart, Tarsus Pharmaceuticals ranks #695 out of 1417 companies for Quick Ratio. This puts Tarsus Pharmaceuticals in the upper half of its industry. The industry median Quick Ratio is 3.60. Tarsus Pharmaceuticals' value of 3.71 is 3.1% above this benchmark. Historically, Tarsus Pharmaceuticals' own Quick Ratio has ranged from 3.71 to 70.85 over the past decade. While the company's 10-year median is 13.75 vs. the industry median of 3.60, Tarsus Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tarsus Pharmaceuticals's current Quick Ratio of 3.71 is 3.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Tarsus Pharmaceuticals and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tarsus Pharmaceuticals's current Quick Ratio is 3.71, which is 73% below median its own 10-year median of 13.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Tarsus Pharmaceuticals (TARS) is currently considered Possible Value Trap. The stock's GF Value™ is $201.69, compared to a current price of $67.11 — trading 66.7% below its estimated fair value. The current Quick Ratio is 3.71, which is 73% below median its 10-year median of 13.75 and 3.1% above the Biotechnology industry median of 3.60. Tarsus Pharmaceuticals' overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Tarsus Pharmaceuticals (TARS), the current Quick Ratio is 3.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tarsus Pharmaceuticals (TARS) Overvalued in 2026?
Based on GuruFocus' analysis, Tarsus Pharmaceuticals stock appears to be undervalued.
The current stock price of $67.11 is trading 66.7% below its estimated GF Value™ of $201.69.
GuruFocus considers Tarsus Pharmaceuticals to be Possible Value Trap.
Key valuation signals for TARS:
Quick Ratio: 3.71 (73% below median its 10-year median of 13.75)
GF Value™: $201.69 vs. price of $67.11 (66.7% below fair value)
Industry Position: 3.1% above the Biotechnology median (#695 of 1417)
No single metric tells the full story. See the TARS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
48GF Score
Get the complete analysis for TARS
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TARS has been successfully added to your 
